A global multi center, randomized clinical trial (ARES study) compared the efficacy of entecavir monotherapy for 48 weeks and ex received en
A global multi center, randomized clinical trial (ARES study) compared the efficacy of entecavir monotherapy for 48 weeks and ex received entecavir for 24 weeks in patients with chronic hepatitis B after the combined use of Pegasys treatment for 24 weeks. The main researchers in Holland Rotterdam Erasmus University School of medicine Sonneveld in the sixty-third session of the American Association for the study of liver diseases at the annual meeting (2012) reported the study result of 48 weeks. The results showed that the levels of HBVDNA, HBsAg and HBeAg decreased significantly after 24 weeks of treatment in the combination group, and the levels of and. After adjusting for baseline HBsAg levels, the addition of new treatment was an independent factor for better outcomes after 48 weeks of treatment. The researchers said that this treatment may cause more accepted entecavir treatment of HBeAg positive chronic hepatitis B patients with limited treatment.
"The results are very encouraging," said a study on liver disease. The combination of two drugs with different mechanisms of action may lead to a higher therapeutic endpoint, HBsAg. However, there are only 48 weeks to go, and we need to follow up on these patients for longer to see how long term outcomes are."